Short Interest in XOMA Co. (NASDAQ:XOMA) Drops By 23.5%

XOMA Co. (NASDAQ:XOMA) saw a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 173,300 shares, a decline of 23.5% from the October 15th total of 226,400 shares. Based on an average daily trading volume, of 22,100 shares, the days-to-cover ratio is currently 7.8 days.

Analyst Upgrades and Downgrades

XOMA has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $117.00 target price on shares of XOMA in a report on Wednesday, October 23rd. StockNews.com raised XOMA from a “sell” rating to a “hold” rating in a research note on Wednesday, August 14th.

Insider Buying and Selling at XOMA

In other XOMA news, CEO Owen Hughes sold 21,881 shares of XOMA stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total value of $655,335.95. Following the transaction, the chief executive officer now directly owns 34,979 shares in the company, valued at approximately $1,047,621.05. The trade was a 38.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in XOMA. Barclays PLC increased its stake in shares of XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after buying an additional 8,447 shares during the last quarter. State Street Corp lifted its holdings in XOMA by 1.2% in the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after acquiring an additional 1,754 shares during the last quarter. BNP Paribas Financial Markets boosted its position in XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 795 shares during the period. Ellsworth Advisors LLC acquired a new position in shares of XOMA during the third quarter valued at $516,000. Finally, Rhumbline Advisers boosted its stake in XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares during the period. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

XOMA Stock Performance

NASDAQ XOMA opened at $30.21 on Friday. The stock has a market cap of $355.96 million, a price-to-earnings ratio of -8.68 and a beta of 0.90. The business has a fifty day moving average of $28.72 and a 200-day moving average of $26.89. XOMA has a fifty-two week low of $14.33 and a fifty-two week high of $33.78. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The business had revenue of $11.09 million during the quarter, compared to analyst estimates of $8.37 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. As a group, analysts predict that XOMA will post -0.79 earnings per share for the current fiscal year.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.